Ed Mathers, Partner at NEA, says, "The Orbis Medicines team has impressed us with the data supporting nGen, which we believe is the world's leading discovery engine for oral macrocycle drugs. We are thrilled to support not only their journey to the clinic but also their longer-term vision as a leader in their field."
Orbis CEO, Graugaard, says, "The support from this particular group of investors is further validation of the exemplary science and exciting potential of Orbis Medicines. The company is advancing the potential of macrocycles by developing orally available nCycles - a format preferred by patients, physicians and healthcare systems, particularly for chronic diseases."
Graugaard's appointment as CEO marks a strategic move for Orbis, as he brings over 20 years of experience in life sciences, vital for navigating the company's growth phase.
Collection
[
|
...
]